Gossamer Bio Inc
GOSS3.080USD
+0.090+3.01%
Close 09/18, 16:00（ET）Quotes delayed by 15 min
700.15MMarket Cap
LossP/E TTM
More Details of Gossamer Bio Inc Company
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH). Its product candidate Seralutinib, also known as GB002, is an investigational inhaled, small molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. In contrast to the three classes of marketed vasodilatory therapies for PAH, its seralutinib has the potential to reverse pathological remodeling by addressing mechanisms that underlie PAH. Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways. In addition to PAH, seralutinib holds the potential as a therapeutic option for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Company Info
Ticker SymbolGOSS
Company nameGossamer Bio Inc
IPO dateFeb 08, 2019
CEOMr. Faheem Hasnain
Number of employees144
Security typeOrdinary Share
Fiscal year-endFeb 08
Address3115 Merryfield Row
CitySAN DIEGO
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code92121
Phone18586841300
Websitehttps://www.gossamerbio.com/
Ticker SymbolGOSS
IPO dateFeb 08, 2019
CEOMr. Faheem Hasnain
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Christian Waage
Mr. Christian Waage
Executive Vice President - Technical Operations and Administration
Executive Vice President - Technical Operations and Administration
666.30K
+1.87%
Dr. Richard Aranda, M.D.
Dr. Richard Aranda, M.D.
Chief Medical Officer
Chief Medical Officer
205.95K
+5.92%
Mr. Faheem Hasnain
Mr. Faheem Hasnain
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
120.29K
--
Dr. Sandra Milligan, M.D., J.D.
Dr. Sandra Milligan, M.D., J.D.
Independent Director
Independent Director
58.05K
+81.41%
Ms. Caryn Peterson
Ms. Caryn Peterson
Executive Vice President - Regulatory Affairs
Executive Vice President - Regulatory Affairs
49.83K
--
Dr. Thomas O. (Tom) Daniel, M.D.
Dr. Thomas O. (Tom) Daniel, M.D.
Lead Independent Director
Lead Independent Director
38.09K
--
Mr. Russell J. Cox
Mr. Russell J. Cox
Independent Director
Independent Director
7.20K
--
Dr. John D. Quisel, J.D., Ph.D.
Dr. John D. Quisel, J.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Robert (Ob) Smith
Mr. Robert (Ob) Smith
Chief Commercial Officer
Chief Commercial Officer
--
--
Dr. Steven D. Nathan, M.D.
Dr. Steven D. Nathan, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Christian Waage
Mr. Christian Waage
Executive Vice President - Technical Operations and Administration
Executive Vice President - Technical Operations and Administration
666.30K
+1.87%
Dr. Richard Aranda, M.D.
Dr. Richard Aranda, M.D.
Chief Medical Officer
Chief Medical Officer
205.95K
+5.92%
Mr. Faheem Hasnain
Mr. Faheem Hasnain
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
120.29K
--
Dr. Sandra Milligan, M.D., J.D.
Dr. Sandra Milligan, M.D., J.D.
Independent Director
Independent Director
58.05K
+81.41%
Ms. Caryn Peterson
Ms. Caryn Peterson
Executive Vice President - Regulatory Affairs
Executive Vice President - Regulatory Affairs
49.83K
--
Dr. Thomas O. (Tom) Daniel, M.D.
Dr. Thomas O. (Tom) Daniel, M.D.
Lead Independent Director
Lead Independent Director
38.09K
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, Aug 15
Updated: Fri, Aug 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Octagon Capital Advisors LP
8.07%
New Enterprise Associates (NEA)
7.96%
The Vanguard Group, Inc.
5.02%
BlackRock Institutional Trust Company, N.A.
4.90%
ARCH Venture Partners
3.54%
Other
70.51%
Shareholders
Shareholders
Proportion
Octagon Capital Advisors LP
8.07%
New Enterprise Associates (NEA)
7.96%
The Vanguard Group, Inc.
5.02%
BlackRock Institutional Trust Company, N.A.
4.90%
ARCH Venture Partners
3.54%
Other
70.51%
Shareholder Types
Shareholders
Proportion
Hedge Fund
27.64%
Investment Advisor
21.11%
Investment Advisor/Hedge Fund
14.50%
Venture Capital
14.24%
Corporation
2.76%
Individual Investor
0.77%
Research Firm
0.49%
Pension Fund
0.10%
Bank and Trust
0.08%
Other
18.32%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
264
183.64M
80.76%
-59.32M
2025Q1
285
180.17M
79.28%
-64.51M
2024Q4
310
181.35M
80.03%
-59.94M
2024Q3
354
184.99M
81.77%
-80.44M
2024Q2
354
192.00M
84.87%
-65.92M
2024Q1
360
205.91M
94.29%
-56.87M
2023Q4
359
215.74M
99.04%
-22.98M
2023Q3
360
211.40M
97.17%
+97.02M
2023Q2
346
75.83M
79.45%
-49.80M
2023Q1
346
90.30M
97.95%
-52.80M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Octagon Capital Advisors LP
18.35M
8.07%
--
--
Mar 31, 2025
New Enterprise Associates (NEA)
18.09M
7.96%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
10.08M
4.44%
+49.73K
+0.50%
Mar 31, 2025
ARCH Venture Partners
8.06M
3.54%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
7.59M
3.34%
-340.02K
-4.29%
Mar 31, 2025
Acadian Asset Management LLC
6.36M
2.8%
+1.25M
+24.55%
Mar 31, 2025
683 Capital Management LLC
6.10M
2.68%
-875.00K
-12.54%
Mar 31, 2025
Samsara BioCapital, LLC
6.13M
2.7%
--
--
Mar 31, 2025
Palo Alto Investors LP
6.28M
2.76%
-200.00
-0.00%
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
